Ajanta Pharma Stock Screener | Share Price & Fundamental Analysis
AJANTPHARM
Pharmaceuticals
Screen Ajanta Pharma share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹2854.00
▲
9.60 (0.34%)
Share Price BSE
₹2853.10
▲
5.90 (0.21%)
Market Cap
₹35,769.07 Cr.
P/E Ratio (TTM)
36.54
P/B Ratio
8.24
EPS (TTM)
₹73.56
Dividend Yield
0.99%
Debt to Equity
0.01
52W High
₹2982.75
52W Low
₹2374.45
Operating Margin
24.00%
Profit Margin
18.40%
Revenue (TTM)
₹1,413.00
EBITDA
₹387.00
Net Income
₹260.00
Total Assets
₹5,015.00
Total Equity
₹3,790.00
Ajanta Pharma Share Price History - Stock Screener Chart
Screen AJANTPHARM historical share price movements with interactive charts. Analyze price trends and patterns.
Ajanta Pharma Company Profile - Fundamental Screener
Screen Ajanta Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for AJANTPHARM shares.
Ajanta Pharma is an Indian specialty pharmaceutical company focusing on branded generic products. It operates in India, Asia, Africa, and the USA, offering a range of therapeutic products including cardiology, dermatology, ophthalmology, and pain management. The company has seven manufacturing facilities in India and Mauritius, with two approved by the...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Mannalal B Agrawal
ISIN
INE031B01049
Website
https://www.ajantapharma.com
Ajanta Pharma Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen AJANTPHARM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 5,015 | 4,638 | 4,679 | 4,056 | 3,779 | 3,319 | 2,696 | 2,449 | 1,848 | 1,481 |
| Current Assets | 2,843 | 2,731 | 2,834 | 2,265 | 2,028 | 1,642 | 1,180 | 1,224 | 851 | 764 |
| Fixed Assets | 1,762 | 1,479 | 1,496 | 1,512 | 1,541 | 1,472 | 1,178 | 1,053 | 589 | 452 |
| Liabilities | ||||||||||
| Total Liabilities | 5,015 | 4,638 | 4,679 | 4,056 | 3,779 | 3,319 | 2,696 | 2,449 | 1,848 | 1,481 |
| Current Liabilities | 229 | 175 | 152 | 144 | 135 | 114 | 73 | 61 | 33 | 38 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 3,790 | 3,567 | 3,388 | 3,264 | 2,996 | 2,599 | 2,245 | 2,041 | 1,568 | 1,172 |
| Share Capital | 25 | 25 | 25 | 17 | 17 | 18 | 18 | 18 | 18 | 18 |
| Reserves & Surplus | 3,765 | 3,542 | 3,363 | 3,247 | 2,978 | 2,581 | 2,228 | 2,024 | 1,550 | 1,154 |
Screen AJANTPHARM income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,413 | 1,329 | 1,189 | 1,177 | 1,206 | 1,171 | 1,090 | 1,119 | 1,050 | 1,053 | 919 | 1,007 | 978 | 984 | 900 |
| Expenses | 1,026 | 951 | 873 | 825 | 876 | 815 | 776 | 791 | 738 | 750 | 733 | 802 | 742 | 729 | 664 |
| EBITDA | 387 | 378 | 315 | 351 | 331 | 357 | 314 | 328 | 312 | 303 | 186 | 205 | 237 | 255 | 236 |
| Operating Profit % | 24.00% | 27.00% | 25.00% | 28.00% | 26.00% | 29.00% | 26.00% | 28.00% | 28.00% | 27.00% | 17.00% | 17.00% | 21.00% | 23.00% | 24.00% |
| Depreciation | 43 | 41 | 40 | 36 | 34 | 34 | 34 | 34 | 34 | 33 | 33 | 33 | 33 | 32 | 31 |
| Interest | 3 | 5 | 6 | 8 | 6 | 1 | 2 | 3 | 2 | 1 | 1 | 3 | 1 | 1 | 7 |
| Profit Before Tax | 341 | 331 | 269 | 307 | 290 | 322 | 278 | 291 | 276 | 269 | 152 | 168 | 203 | 222 | 198 |
| Tax | 81 | 76 | 44 | 75 | 74 | 76 | 75 | 81 | 81 | 61 | 30 | 34 | 46 | 47 | 47 |
| Net Profit | 260 | 255 | 225 | 233 | 217 | 246 | 203 | 210 | 195 | 208 | 122 | 135 | 157 | 175 | 151 |
| EPS | 20.83 | 20.44 | 18.00 | 18.60 | 17.27 | 19.54 | 16.10 | 16.68 | 15.51 | 16.53 | 9.54 | 10.50 | 12.22 | 13.63 | 17.70 |
Ajanta Pharma Cash Flow Screener - Liquidity Fundamentals
Screen AJANTPHARM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 1,157 | 785 | 792 | 562 | 576 | 457 | 375 | 281 | 609 | 326 |
| Investing Activities | -377 | 65 | -560 | -74 | -282 | -224 | -223 | -256 | -383 | -209 |
| Financing Activities | -733 | -1,051 | -108 | -460 | -318 | -129 | -148 | 0 | -202 | -117 |
| Net Cash Flow | 47 | -201 | 124 | 28 | -24 | 104 | 4 | 25 | 24 | 0 |
Screen AJANTPHARM shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 66.25% | 66.26% | 66.26% | 66.26% | 66.26% | 66.27% | 66.21% | 66.21% |
| FII Holding | 8.53% | 8.86% | 8.86% | 9.26% | 9.11% | 8.36% | 8.54% | 0.00% |
| DII Holding | 17.90% | 17.50% | 17.48% | 17.02% | 17.10% | 17.41% | 17.49% | 16.01% |
| Govt Holding | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.00% | 0.00% |
| Public Holding | 6.53% | 6.59% | 6.63% | 6.67% | 6.71% | 7.08% | 6.91% | 7.07% |
| Other Holding | 0.79% | 0.79% | 0.76% | 0.79% | 0.80% | 0.86% | 0.84% | 10.70% |
| Shareholder Count | 67,785 | 68,882 | 70,827 | 66,896 | 64,315 | 70,316 | 55,488 | 54,351 |
Ajanta Pharma Dividend Screener - Share Yield Analysis
Screen AJANTPHARM dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹28.00 | 0.98% |
| 2024-March | ₹51.00 | 1.94% |
| 2023-March | ₹7.00 | 0.31% |
| 2022-March | ₹9.50 | 0.79% |
| 2021-March | ₹9.50 | 0.79% |
| 2020-March | ₹13.00 | 1.09% |
| 2019-March | ₹9.00 | 0.99% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹13.00 | 1.40% |
Ajanta Pharma Index Membership - Market Screener Classification
Screen AJANTPHARM by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Ajanta Pharma Market Events Screener - Corporate Actions
Screen AJANTPHARM market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2025-11-10 | 2025-11-10 | Dividend | ₹ 28.00 /share | 2.50% |
| 2025-11-03 | 2025-11-03 | Quarterly Result Announcement | NA | 0.20% |
| 2025-07-28 | 2025-07-28 | Quarterly Result Announcement | NA | 3.00% |
| 2025-07-17 | 2025-07-17 | Annual General Meeting | NA | 5.31% |
| 2025-04-30 | 2025-04-30 | Quarterly Result Announcement | NA | 3.24% |
| 2025-01-30 | 2025-01-30 | Quarterly Result Announcement | NA | -8.46% |
| 2024-11-06 | 2024-11-06 | Dividend | ₹ 28.00 /share | 4.74% |
| 2024-10-28 | 2024-10-28 | Quarterly Result Announcement | NA | -11.03% |
| 2024-07-18 | 2024-07-18 | Annual General Meeting | NA | -8.03% |
| 2024-05-30 | 2024-06-05 | Buyback | 2770 | -5.13% |
| 2024-02-08 | 2024-02-08 | Dividend | ₹ 26.00 /share | 6.89% |
| 2023-08-04 | 2023-08-04 | Dividend | ₹ 10.00 /share | 11.34% |
| 2023-08-04 | 2023-08-04 | Dividend | ₹ 15.00 /share | 11.34% |
| 2023-03-24 | 2023-03-31 | Buyback | 1425 | -5.17% |
| 2022-11-11 | 2022-11-14 | Dividend | ₹ 7.00 /share | -6.68% |
Ajanta Pharma Competitors Screener - Peer Comparison
Screen AJANTPHARM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 422,811 | 40.28 | 54,729 | 9.71% | 10,980 | 53.13 |
| Divis Laboratories | 176,072 | 70.98 | 9,712 | 18.67% | 2,191 | 63.15 |
| Torrent Pharmaceuticals | 136,861 | 62.26 | 11,539 | 6.99% | 1,911 | 71.28 |
| Cipla | 118,492 | 22.75 | 28,410 | 7.12% | 5,291 | 57.84 |
| Dr Reddys Laboratories | 103,753 | 18.27 | 33,741 | 16.73% | 5,725 | 46.16 |
| Lupin | 100,441 | 22.61 | 22,910 | 13.74% | 3,306 | 63.46 |
| Mankind Pharma | 94,532 | 52.17 | 12,744 | 20.90% | 2,007 | 56.13 |
| Zydus Life Science | 93,057 | 18.63 | 23,511 | 18.55% | 4,615 | 54.52 |
| Aurobindo Pharma | 71,985 | 20.91 | 32,346 | 9.43% | 3,484 | 60.21 |
| Alkem Laboratories | 69,216 | 28.04 | 13,458 | 3.70% | 2,216 | 55.49 |
Ajanta Pharma Company Announcements - News Screener
Screen AJANTPHARM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-08 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2026-01-02 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | View |
| 2026-01-01 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | View |
| 2025-12-26 | Closure of Trading Window | View |
| 2025-12-23 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-12-19 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | View |
| 2025-12-10 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | View |
| 2025-11-28 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | View |
| 2025-11-13 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011 | View |
| 2025-11-06 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-11-04 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-03 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-11-03 | Announcement under Regulation 30 (LODR)-Change in Registered Office Address | View |
| 2025-11-03 | Corporate Action- Record Date Fixation | View |
| 2025-11-03 | Corporate Action-Board approves Dividend | View |
| 2025-11-03 | Unaudited Financial Results For The Quarter And Half Year Ended 30.09.2025 | View |
| 2025-11-03 | Board Meeting Outcome for Board Meeting Outcome | View |
| 2025-10-24 | Corporate Action- Fixation Of Record Date For 1St Interim Dividend | View |
| 2025-10-24 | Corporate Action-Board to consider Dividend | View |
| 2025-10-24 | Update on board meeting | View |